Source: ERS Course 2021 - COVID-19: State of the art



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cavaleri (Amsterdam, Netherlands). Regulatory status of COVID-19 vaccines. ERS Course 2021 - COVID-19: State of the art

Member's Comments

No comment yet.

Related content which might interest you: Regulatory aspects of respiratory drugs Source: Research Seminar 2014 - Breaking down barriers to lung health: a better environment for better medicines Year: 2014 State of the art in vaccine development against TB Source: Eur Respir Mon 2012; 58: 59-71 Year: 2012 Age and impact of vaccine on seasonal H1N1p severe infection Source: International Congress 2016 – Viral infections in different respiratory conditions: from the bedside to the lab Year: 2016 Regulatory T-cells as a means of controlling immune responses Source: Annual Congress 2003 - Scientific year in review: From molecular mechanisms to new treatments of respiratory diseases Year: 2003 Development of RSV vaccines: where are we? Source: International Congress 2019 – Respiratory syncytial virus infections throughout life Year: 2019 Regulatory B cell development by helminth-derived antigens Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 Protective capacity of a new TB vaccine Source: International Congress 2018 – New developments in tuberculosis Year: 2018 Indicators of immune status among children with pertussis Source: Eur Respir J 2005; 26: Suppl. 49, 407s Year: 2005 Understanding new vaccines for SARS-CoV-2 and their regulation Source: ERS webinar 2021: Understanding new vaccines for SARS-CoV-2 and their regulation Year: 2021 Effects on innate immunity in swine farmers after treatment with steroids Source: International Congress 2014 – Exposure measurement and biological effects of pollutants at work, outdoor and at home Year: 2014 Regulatory T cells in human asthma Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation Year: 2010 Regulatory T-cells in sarcoidosis Source: Annual Congress 2008 - Invasive and noninvasive measurements of lung inflammation Year: 2008 Human immune recognition-based multicomponent subunit vaccines against tuberculosis Source: Eur Respir J 2005; 25: 902-910 Year: 2005 Regulatory perspective on the use of lung imaging in drug development Source: Eur Respir Monogr 2015; 70: 233-252 Year: 2015 New Influenza vaccines Source: Virtual Congress 2021 – Vaccination and infections Year: 2021 The allergen-specific immunotherapy efficiency in dependent on patient’s parasitic status Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Influenza surveillance and vaccination: new developments Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017 Pneumococcal vaccine: clinical factors as facilitators or barriers to vaccination Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005